Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

US10844122B2 · kind B2 · utility

Assignee

• JANSSEN BIOTECH, INC. · US

Inventors

• Glenn Mark Anderson · San Ramon, US
• Rosa Cardoso · Spring House, US
• Michael Diem · Havertown, US
• Francois Gaudet · Princeton, US
• Shalom Goldberg · Cynwyd Estates, US
• Benjamin Harman · Spring House, US
• Linus Hyun · Radnor, US
• Steven Jacobs · North Wales, US
• Donna Klein · Philadelphia, US
• Yingzhe Li · Dresher, US
• Jinquan Luo · Malvern, US
• Ronan McDaid · Eagleville, US
• Jill Mooney · San Diego, US
• Jennifer Nemeth-Seay · Fort Washington, US
• Karyn O'Neil · Spring House, US
• Steven Pomerantz · Spring House, US
• Galla Chandra Rao · Princeton, US
• Tracy Spinka-Doms · Spring House, US
• Alexey Teplyakov · Spring House, US
• Leopoldo L. Luistro, III · Lansdale, US
• Sheng-Jiun Wu · Broomall, US

Key dates

• Filing date: May 6, 2016
• Grant date: Nov 24, 2020
• Expiry date: Jun 24, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.